GlassScriptPhysician profile
Kurtis M Munzer
NPI 1396087540
$7,272.14
in general payments reported to CMS, 2019-2025
20 companies · $5,343 in 2025
The $5,343 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $38.07 · 2021: $18.10 · 2022: $58.47 · 2023: $245 · 2024: $603 · 2025: $5,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Food and Beverage: $1,563 · Travel and Lodging: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Food and Beverage | $1,562.83 |
| Travel and Lodging | $879.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,006.38 | 2022-2025 | Breztri, Airsupra, Fasenra |
| Intuitive Surgical, INC. | $992.24 | 2025 | |
| Veran Medical Technologies, INC. | $836.48 | 2019 | |
| Glaxosmithkline, LLC. | $255.29 | 2020-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $229.51 | 2019-2024 | Uptravi, Opsumit |
| Genzyme Corporation | $204.11 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.86 | 2022-2025 | Ofev |
| Medtronic, INC. | $105.96 | 2024 | Illumisite |
| United Therapeutics Corporation | $81.71 | 2023-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $80.15 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $72.29 | 2023-2024 | Dupixent |
| Insmed, INC. | $66.18 | 2024-2025 | Brinsupri, Arikayce |
| Viatris Specialty LLC | $58.82 | 2025 | Yupelri |
| Lilly USA, LLC | $42.57 | 2025 | Zepbound, Mounjaro |
| Verona Pharma, INC. | $41.62 | 2025 | Ohtuvayre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.82 | 2023 | |
| Resmed Corp | $18.10 | 2021 | |
| Pfizer INC. | $15.23 | 2024 | |
| Merck Sharp & Dohme LLC | $14.30 | 2023 | |
| Advanced Respiratory, INC | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurtis Munzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.